{
    "nct_id": "NCT05787028",
    "title": "Safety, Tolerability and Pharmacokinetics of AD16 Tablets in Adult Healthy Subjects After Single Administration",
    "status": "COMPLETED",
    "last_update_time": "2023-11-28",
    "description_brief": "The primary objective of this study was to evaluate the safety, tolerability and pharmacokinetic characteristics of single administration of AD16 tablets in healthy adults under fasting conditions, and the secondary objective was to preliminarily evaluate the material balance of single administration of AD16 tablets in fasting conditions.\n\nThe study is divided into two parts: preliminary test and formal test. The formal trial was a single-center, randomized, placebo-controlled, double-blind, dose-increasing study, with 5 dose groups (5mg, 10mg, 20mg, 30mg and 40mg, respectively).\n\nTen subjects (male and female) were enrolled in each dose group, of which 8 received the experimental drug and 2 received placebo.\n\nUrine and fecal samples were collected in the 20mg dose group for material balance study.Urine and fecal samples were collected in the 20mg dose group for material balance study.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "AD16"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The trial tests AD16 tablets in healthy adults to evaluate safety, tolerability, PK and mass balance after single oral doses (5\u201340 mg). The described objectives and design match a first-in-human pharmacokinetic/safety SAD study rather than a symptomatic-only trial, implying a disease-modifying development goal.",
        "Act \u2014 key evidence & web search results: AD16 is described in the literature as a novel anti-neuroinflammatory compound that modulates microglia, reduces amyloid plaque deposition in AD mouse models, and was progressed into Phase I studies assessing single and multiple ascending oral doses in healthy adults. \ue200cite\ue202turn0search3\ue202turn0search0\ue201",
        "Act \u2014 trial match: The published Phase 1 report and trial registry describe single-center, randomized, placebo-controlled, double-blind single-ascending-dose groups of 5, 10, 20, 30 and 40 mg with 10 subjects per group (8 active, 2 placebo) and material-balance sampling in the 20 mg group \u2014 matching your description. \ue200cite\ue202turn0search0\ue202turn0search1\ue201",
        "Interpretation: AD16 is a small-molecule investigational drug (chemical structure shown in the Phase I paper) targeting neuroinflammation/microglial function and with effects on amyloid pathology in preclinical models \u2014 therefore it is best classified as a disease-targeted small molecule (a small-molecule agent aimed at Alzheimer\u2019s pathology). \ue200cite\ue202turn0search0\ue202turn0search3\ue201",
        "Reflect: The trial is not a symptomatic cognitive-enhancer trial nor a neuropsychiatric symptom study; it is an early-stage safety/PK study of a candidate that aims to modify disease-relevant biology (neuroinflammation/amyloid handling). Classification as 'disease-targeted small molecule' aligns with the mechanism (anti\u2011neuroinflammatory, microglial modulation) and the fact that AD16 is a chemical small molecule shown with a chemical structure in the Phase 1 report. \ue200cite\ue202turn0search0\ue202turn0search3\ue201",
        "Web search results consulted (selected):",
        "1) BMC Medicine 2023 \u2014 'Safety, tolerability, pharmacokinetics and effects of diet on AD16, a novel neuroinflammatory inhibitor for Alzheimer\u2019s disease: a randomized phase 1 study' (Phase I SAD/MAD/food-effect reporting PK, safety, dose groups as above). \ue200cite\ue202turn0search0\ue201",
        "2) PubMed entry for the Phase I study (summary and trial registrations NCT05787028, NCT05787041, NCT05806177). \ue200cite\ue202turn0search1\ue201",
        "3) ACS Pharmacology & Translational Science 2020 \u2014 preclinical work: 'Compound AD16 Reduces Amyloid Plaque Deposition and Modifies Microglia in a Transgenic Mouse Model of Alzheimer\u2019s Disease' (mechanistic/preclinical data showing microglial modulation and plaque effects). \ue200cite\ue202turn0search3\ue201",
        "4) Additional preclinical reports describing neuroprotective/anti-inflammatory effects of AD-16 in other brain-injury models (supporting its anti-neuroinflammatory profile). \ue200cite\ue202turn0search4\ue201",
        "Ambiguity/limitations: The trial text you provided is a Phase I PK/safety study in healthy adults (no efficacy endpoints). The classification relies on published preclinical and Phase I descriptions indicating AD16 is a small molecule aimed at neuroinflammation/AD pathology; if AD16 were later shown to be a biologic or reclassified, the category would need revision \u2014 current sources identify it as a chemical small-molecule candidate. \ue200cite\ue202turn0search0\ue202turn0search3\ue201"
    ],
    "agent_type": "F) Inflammation",
    "explanation_agent": [
        "Reason: AD16 is described in preclinical and clinical reports as an anti\u2011neuroinflammatory small molecule that modulates microglial function and thereby affects Alzheimer\u2019s\u2011relevant biology (microglial activation, lysosomal function and reduced plaque deposition). This mechanism maps to CADRO category F (Inflammation). \ue200cite\ue202turn0search0\ue202turn0search4\ue201",
        "Act: Key evidence \u2014 preclinical work (ACS Pharmacol. Transl. Sci. 2020) shows AD16 modifies microglia and reduces amyloid plaque deposition in AD mouse models; Phase I clinical reports (BMC Medicine / PubMed) describe single\u2011 and multiple\u2011ascending oral dose SAD/MAD/food\u2011effect studies in healthy adults assessing safety, tolerability and PK (SAD groups 5\u201340 mg), confirming AD16 is a disease\u2011targeted small\u2011molecule developed for its anti\u2011neuroinflammatory action. \ue200cite\ue202turn0search0\ue202turn0search4\ue202turn0search1\ue201",
        "Act \u2014 trial match: The cited Phase I paper and registry entries (NCT05787028, NCT05787041, NCT05806177) report the randomized, placebo\u2011controlled SAD/MAD and food\u2011effect designs described in your prompt, consistent with an early\u2011stage safety/PK study of a candidate targeting neuroinflammation. \ue200cite\ue202turn0search1\ue202turn0search2\ue201",
        "Reflect: Classification as F) Inflammation is the most specific CADRO match because the primary mechanistic description is anti\u2011neuroinflammatory/microglial modulation (not a direct anti\u2011amyloid antibody, tau agent, neurotransmitter symptomatic treatment, or non\u2011therapeutic diagnostic). Although preclinical data note secondary effects on amyloid plaques, the agent\u2019s stated target/pathway is inflammation/microglia, so F) Inflammation is appropriate. If future data reclassify AD16\u2019s mechanism (e.g., primary direct amyloid-binding), the CADRO category should be reassessed. \ue200cite\ue202turn0search0\ue202turn0search4\ue201",
        "Web search results consulted (selected): 1) ACS Pharmacology & Translational Science 2020 \u2014 \"Compound AD16 Reduces Amyloid Plaque Deposition and Modifies Microglia\u2026\" (preclinical microglia/anti\u2011inflammatory mechanism). \ue200cite\ue202turn0search0\ue201 2) BMC Medicine 2023 / PMC \u2014 \"Safety, tolerability, pharmacokinetics and effects of diet on AD16\u2026\" (Phase I SAD/MAD/food\u2011effect; chemical structure; PK/safety in healthy adults). \ue200cite\ue202turn0search2\ue202turn0search4\ue201 3) PubMed entry summarizing the Phase I study and listing ClinicalTrials.gov identifiers. \ue200cite\ue202turn0search1\ue201"
    ]
}